The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
Open accessAbstract
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammatory conditions of the gastrointestinal tract that are driven by perturbed cytokine pathways. Anti-tumor necrosis factor-α (TNF) antibodies are mainstay therapies for IBD. However, up to 40% of patients are nonresponsive to anti-TNF agents, which makes the identification of alternative therapeutic targets a priority. Here we show that, relative to healthy controls, inflamed intestinal tissues from patients with IBD express high amounts of the cytokine oncostatin M (OSM) and its receptor (OSMR), which correlate closely with histopathological disease severity. The OSMR is expressed in nonhematopoietic, nonepithelial intestinal stromal cells, which respond to OSM by producing various proinflammatory molecules, including interleukin (IL)-6, the leukocyte adhesion factor ICAM1, and chemokines that attract neutrophils, monocytes, and T cells. In an animal model of anti-TNF-resistant intestinal inflammation, genetic deletion or pharmacological blockade of OSM significantly attenuates colitis. Furthermore, according to an analysis of more than 200 patients with IBD, including two cohorts from phase 3 clinical trials of infliximab and golimumab, high pretreatment expression of OSM is strongly associated with failure of anti-TNF therapy. OSM is thus a potential biomarker and therapeutic target for IBD, and has particular relevance for anti-TNF-resistant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationGuilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., & Morel, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902464 · Cited by 353
Essential Function of Oncostatin M in Nociceptive Neurons of Dorsal Root Ganglia
Morikawa, Y., Tamura, S., Minehata, K.-I., Donovan, P. J., Miyajima, A., & Senba, E. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4975-03.2004 · Cited by 80
Cited by
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Pathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Macrophages in health and disease
Park, M. D., Silvin, A., Ginhoux, F., & Merad, M. (2022) · Cell · doi:10.1016/j.cell.2022.10.007 · Cited by 644
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.001 · Cited by 484
Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease
Lee, J.-Y., Hall, J. A., Kroehling, L., Wu, L., Najar, T., Nguyen, H. H., Lin, W.-Y., Yeung, S. T., Silva, H. M., Li, D., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.026 · Cited by 466
Martini, E., Kunderfranco, P., Peano, C., Carullo, P., Cremonesi, M., Schorn, T., Carriero, R., Termanini, A., Colombo, F. S., Jachetti, E., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041694 · Cited by 341
Gisbert, J. P., & Chaparro, M. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz195 · Cited by 281
Schreiber, S., Aden, K., Bernardes, J. P., Conrad, C., Tran, F., Höper, H., Volk, V., Mishra, N., Blase, J. I., Nikolaus, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.062 · Cited by 259
Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis
Castro-Dopico, T., Dennison, T. W., Ferdinand, J. R., Mathews, R. J., Fleming, A., Clift, D., Stewart, B. J., Jing, C., Strongili, K., Labzin, L. I., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.006 · Cited by 248
Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer
Rajamäki, K., Taira, A., Katainen, R., Välimäki, N., Kuosmanen, A., Plaketti, R.-M., Seppälä, T. T., Ahtiainen, M., Wirta, E.-V., Vartiainen, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.042 · Cited by 230
Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Ruder, B., Atreya, R., & Becker, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081887 · Cited by 228
“This is best exemplified by recent studies where elevated pre-treatment expression of intestinal oncostatin-M [170] in mucosal plasma cells and inflammatory macrophages were associated with failure to anti-TNFα therapy [171].”
ResultPott, J., Kabat, A. M., & Maloy, K. J. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.017 · Cited by 205
Self-citationPositioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
Giraldez, M. D., Carneros, D., Garbers, C., Rose-John, S., & Bustos, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00473-x · Cited by 156
Aschenbrenner, D., Quaranta, M., Banerjee, S., Ilott, N., Jansen, J., Steere, B., Chen, Y.-H., Ho, S., Cox, K., Arancibia-Cárcamo, C. V., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321731 · Cited by 123
Self-citationA short field guide to fibroblast function in immunity
Buechler, M. B., & Turley, S. J. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.11.001 · Cited by 121
Oncostatin M and its role in fibrosis
Stawski, L., & Trojanowska, M. (2019) · Connective Tissue Research · doi:10.1080/03008207.2018.1500558 · Cited by 86
Approaches and advances in the genetic causes of autoimmune disease and their implications
Inshaw, J. R. J., Cutler, A. J., Burren, O. S., Stefana, M. I., & Todd, J. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0129-8 · Cited by 70
Cheng, Y., Hall, T. R., Xu, X., Yung, I., Souza, D., Zheng, J., Schiele, F., Hoffmann, M., Mbow, M. L., Garnett, J. P., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103758 · Cited by 66
Giachero, F., Jenke, A., & Zilbauer, M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1945442 · Cited by 7
Metadata
- Authors
- Oxford IBD Cohort Investigators, West, N. R., Hegazy, A. N., Owens, B. M. J., Bullers, S. J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This, S., Stockenhuber, K., Pott, J., Friedrich, M., Ryzhakov, G., Baribaud, F., Brodmerkel, C., Cieluch, C., Rahman, N., Müller-Newen, G., Owens, R. J., Kühl, A. A., Maloy, K. J., Plevy, S. E., Keshav, S., Travis, S. P. L., & Powrie, F.
- Venue
- Nature Medicine
- Published
- 2017-04-03
- Volume
- 23
- Issue
- 5
- Pages
- 579-589
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2604780989
- Cited by
- 811
- References
- 4
- FWCI
- 38.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
